- Home
- HLXB vs OMER Comparison
HLXB vs OMER Comparison
Compare HLXB & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLXB
- OMER
- Stock Information
- Founded
- HLXB 2021
- OMER 1994
- Country
- HLXB United States
- OMER United States
- Employees
- HLXB N/A
- OMER N/A
- Industry
- HLXB
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- HLXB
- OMER Health Care
- Exchange
- HLXB NYSE
- OMER Nasdaq
- Market Cap
- HLXB 243.6M
- OMER 240.5M
- IPO Year
- HLXB 2024
- OMER 2009
- Fundamental
- Price
- HLXB $10.47
- OMER $4.49
- Analyst Decision
- HLXB
- OMER Hold
- Analyst Count
- HLXB 0
- OMER 2
- Target Price
- HLXB N/A
- OMER N/A
- AVG Volume (30 Days)
- HLXB 9.2K
- OMER 202.7K
- Earning Date
- HLXB 01-01-0001
- OMER 11-11-2024
- Dividend Yield
- HLXB N/A
- OMER N/A
- EPS Growth
- HLXB N/A
- OMER N/A
- EPS
- HLXB N/A
- OMER N/A
- Revenue
- HLXB N/A
- OMER N/A
- Revenue This Year
- HLXB N/A
- OMER N/A
- Revenue Next Year
- HLXB N/A
- OMER N/A
- P/E Ratio
- HLXB N/A
- OMER N/A
- Revenue Growth
- HLXB N/A
- OMER N/A
- 52 Week Low
- HLXB $10.03
- OMER $1.13
- 52 Week High
- HLXB $10.83
- OMER $5.68
- Technical
- Relative Strength Index (RSI)
- HLXB N/A
- OMER 63.45
- Support Level
- HLXB N/A
- OMER $4.01
- Resistance Level
- HLXB N/A
- OMER $4.68
- Average True Range (ATR)
- HLXB 0.00
- OMER 0.19
- MACD
- HLXB 0.00
- OMER 0.03
- Stochastic Oscillator
- HLXB 0.00
- OMER 73.13
About HLXB HELIX ACQUISITION CORP. II
Helix Acquisition Corp II is a Blank check company.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.